Share:
According to Coherent Market Insights, the global progressive supranuclear palsy treatment market is estimated to be valued at US$ 14.38 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).
Key Trends and Analysis:
Key trends in the market include rising incidence of progressive supranuclear palsy and ongoing research and development for treatment.
Market players are actively focusing research and development for
progressive supranuclear palsy treatment for cost effective and quality treatment. For instance, in July 2018, Asceneuron, a Switzerland-based biotechnology company received orphan drug designation, for its lead drug ASN120290 from the U.S. Food and Drug Administration (FDA). ASN120290 s therapeutic potential has been demonstrated in pre-clinical studies, indicated for the treatment of rare neurodegenerative disease, progressive supranuclear palsy (PSP).
Global Progressive Supranuclear Palsy Treatment Market to Surpass US$ 20 68 Million by 2027, Says Coherent Market Insights (CMI) - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.